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The functional relevance of reactive gliosis for recovery from acute unilateral vestibu-
lopathy is unknown. In the present study, glial activation was visualized in vivo by [18F]
GE180-PET in a rat model of unilateral labyrinthectomy (UL) and compared to behavioral 
vestibular compensation (VC) overtime. 14 Sprague-Dawley rats underwent a UL by 
transtympanic injection of bupivacaine/arsenilate, 14 rats a SHAM UL (injection of normal 
saline). Glial activation was depicted with [18F]GE180-PET and ex vivo autoradiography 
at baseline and 7, 15, 30 days after UL/SHAM UL. Postural asymmetry and nystag-
mus were registered at 1, 2, 3, 7, 15, 30 days after UL/SHAM UL. Signs of vestibular 
imbalance were found only after UL, which significantly decreased until days 15 and 
30. In parallel, [18F]GE180-PET and ex vivo autoradiography depicted glial activation 
in the ipsilesional vestibular nerve and nucleus on days 7 and 15 after UL. Correlation 
analysis revealed a strong negative association of [18F]GE180 uptake in the ipsilesional 
vestibular nucleus on day 7 with the rate of postural recovery (R = −0.90, p < 0.001), 
suggesting that glial activation accelerates VC. In conclusion, glial activation takes place 
in the ipsilesional vestibular nerve and nucleus within the first 30 days after UL in the rat 
and can be visualized in vivo by [18F]GE180-PET.
Keywords: glial activation, vestibular compensation, small animal PeT, translocator protein imaging, acute 
unilateral vestibulopathy
inTrODUcTiOn
Acute unilateral vestibulopathy (AUV) induces spontaneous nystagmus, head roll tilt, and falling 
to the lesion side (1, 2). Signs and symptoms recover over days to weeks due to central vestibular 
compensation (VC) (3). Therefore, VC is an interesting model for studying post-lesional plasticity 
in the adult intact brain (4). Several hypotheses have been proposed to explain VC. It is commonly 
accepted that VC is not a single process but involves multiple, synchronous, and synergistic adap-
tations in neuronal networks of various brain areas (5–9). The cellular and molecular mechanisms 
are still not completely understood. Microglial cells play an important role in brain plasticity 
following neuronal damage by modulating synaptic function, neurotransmission, and immune 
Table 1 | Overview of the number of animals included in molecular imaging 
modalities and behavioral testing during the experiment.
baseline (N = 32) PeT (N) ar/hc (N)
6 4
surgery (N = 28) Ul (N = 14) shaM-Ul (N = 14)
PeT ar/hc behavior PeT ar/hc behavior
D1 (N) – – 14 – – 14
D2 (N) – – 14 – – 14
D3 (N) – – 14 – – 14
D7 (N) 10 4 14 6 4 14
D15 (N) 10 4 10 5 4 10
D30 (N) 4 4 6 5 4 6
PET, [18F]GE180-PET; AR, ex vivo autoradiography; HC, histochemistry; N, number of 
animals; UL, unilateral labyrinthectomy.
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response (10, 11). Glial reactions in the ipsilesional vestibular 
nucleus (VN) after inner ear damage have been depicted by 
in  vitro histochemistry (12–14). The functional relevance of 
microglia activation for vestibular nerve regeneration and 
central VC following inner ear damage is not known.
The 18 kDa translocator protein (TSPO), formerly known as 
peripheral-type benzodiazepine receptor, is a well-established 
marker for activated microglia (15, 16). It is predominantly located 
in the mitochondrial membrane and modulates the synthesis of 
neurosteroids (17). In the central nervous system (CNS), TSPO is 
expressed in microglia and in reactive astrocytes (16). In response 
to peripheral nerve injury, TSPO is upregulated in Schwann cells, 
macrophages, and neurons (18, 19). TSPO expression returns to 
resting levels only when nerve regeneration is completed, sug-
gesting it plays an important role in nerve repair processes (20).
The aim of this study is to visualize vestibular nerve and cer-
ebral glial activation after unilateral labyrinthectomy (UL) in rats 
in vivo and in correlation to behavior using PET with the novel 
TSPO ligand [18F]GE180 (21). The major advantage of this model 
is that it closely resembles the clinical picture of AUV, the most 
common cause of acute vertigo persisting for days. The present 
pilot study concentrates on the intermediate and late phases of 
postural compensation following a unilateral vestibular lesion.
MaTerials anD MeThODs
animals and experimental Design
All animal experiments were approved by the Ethics committee of 
the University of Munich and the government of Upper Bavaria 
(number of license: 55.2-1-54-2532-93-16) and performed in 
accordance with the guidelines for the use of living animals in 
scientific studies and the EU and German Law for the protection 
of animals. Male Sprague-Dawley rats (mean 400 ±  20  g, age 
3 months, Charles River Ltd., UK) were housed one animal per 
cage in a temperature- and humidity-controlled room with a 12-h 
light/dark cycle, with free access to food and water.
The study was conducted in a partial longitudinal design 
(Table 1): from the 32 animals included in the experiment a base-
line PET scan was performed prior to surgery in a randomized 
subgroup of six rats among which four were sacrificed for auto-
radiography and histology. The remaining rats were randomized 
into two groups of 14 animals to undergo either UL or SHAM-UL. 
PET was performed on day 7 (UL: N = 10, SHAM-UL: N = 6), 
day 15 (UL: N = 10, SHAM-UL: N = 5), and day 30 (UL: N = 4; 
SHAM-UL: N = 5). At each post-UL/SHAM-UL PET time point, 
four rats were sacrificed for ex vivo autoradiography and histol-
ogy. Behavioral testing was performed in all available rats on days 
1, 2, 3, 7 (UL/SHAM-UL: N = 14 each time point), day 15 (UL/
SHAM-UL: N = 10), and day 30 (UL/SHAM-UL: N = 6) after 
surgery. Figure 1 illustrates the study design.
Unilateral labyrinthectomy
Unilateral labyrinthectomy was performed as described in 
previous studies (22–25). Animals were anesthetized with 1.5% 
isoflurane delivered up to 1.2 l/min via a mask. For surgical anal-
gesia, 1 mg/kg meloxicam was injected s.c. before and 3 days after 
surgery. After local anesthesia with 1% lidocaine hydrochloride, a 
left paramedian incision was made to expose the lamboidal ridge 
and the external ear canal. The external ear canal was opened 
just anterior to the exit point of the facial nerve. With a 26-gauge 
needle, the tympanic membrane was perforated caudally to the 
hammer shaft, and about 200 µl of a 20% bupivacaine solution 
was instilled into the tympanic cavity. After about 1  min, the 
bupivacaine solution was aspirated and instilled slowly again. 
This process was repeated three times. After the local anesthetic 
was instilled, the same procedure was performed to instill 
200 µl of a 10% solution of p-arsanilic acid, which irreversibly 
desensitized the primary sensory cells of the inner ear (26). In 
the control group, 200 µl of 0.9% saline was instilled three times 
into the tympanic cavity [in the following the process is called 
sham unilateral labyrinthectomy (SHAM-UL)]. After the last 
thorough aspiration, the wound was closed by skin suture and 
1 mg/kg marbofloxacine was injected s.c. for 3 days for preventive 
antibiosis.
criteria for exclusion
Animals were excluded from the study if the following symptoms 
were observed:
 – loss of more than 20% of the pre-treatment body weight,
 – ulcer of the cornea, which could occur due to an inadvertent 
lesion of the facial nerve,
 – bleeding from the tympanic cavity, which could prevent the 
diffusion of bupivacaine or p-arsanilic acid into the inner ear,
 – abnormality in behavioral scoring, e.g., convulsions, paresis, 
or hemiataxia.
behavioral Testing after Ul/shaM-Ul
The behavioral symptoms of vestibular imbalance nystagmus 
and postural asymmetry were scored after unilateral vestibular 
ablation (27). Each component was given a maximum score of 10:
 – Postural deficits were scored as follows: spontaneous barrel 
rolling—10 points; barrel rolling evoked by a light touch or 
air-puff—9 points; recumbent position on lesion side with-
out leg support—8 points; some ipsilesional leg support—7 
FigUre 1 | Study design for the rat unilateral labyrinthectomy (UL) model. (a) The timeline illustrates the different assessments and modalities in relation to the day 
of surgery. (b) The upper image represents a typical summed 60–90 min [18F]GE180 PET scan of the rat head in the axial direction. Localization of UL with 
corresponding translocator protein (TSPO) activation in the inner ear is indicated by a white circle. The white stippled line represents the position of the intact brain. 
The lower image represents a typical [18F]GE180 autoradiography slice of the brainstem, where elevated TSPO activity in the vestibular nucleus is highlighted with a 
red arrow. L, left; R, right.
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points; moving around on one side or using ipsilesional legs 
for recumbent support—6 points; moving around with bilat-
eral leg support—5 points; moving around with occasional 
falls to the ipsilesional side—4 points; moving around lean-
ing toward the ipsilesional side—3 points; hardly noticeable 
asymmetry—2 points; postural asymmetry only noticeable 
when picked up—1 point;
 – Nystagmus was observed visually. Intensity of spontaneous 
nystagmus was scored with 6–10 points, with 1 point for every 
60 beats per minute (bpm). If spontaneous nystagmus was 
absent at rest, the animal was touched slightly. If this evoked 
nystagmus, a score of 1–5 points was given, with 1 point for 
every 60 bpm.
The estimated function of VC was calculated by using serial 
postural instability scores starting on day 2 post surgery and end-
ing at the final observation point (≥day 7) of individual rats. Day 
1 was excluded to avoid any bias from delayed anesthesia effects. 
Thus, a minimum of three observation points were considered for 
each rat. For each rat, the average change per day was computed 
by the slope of the linear function.
[18F]ge180 synthesis
Automated production of GE180 was performed on a FASTlabTM 
(GE Healthcare) synthesizer with single-use disposable cassettes 
(28). The pre-filled precursor vial was assembled on the cassette, 
and the cassette was mounted on the synthesizer according to 
the set-up instructions. The FASTlabTM control software prompts 
were followed to run the cassette test and to start the synthesis. 
No carrier added 18F-fluoride was produced via 18O(p, n)18F reac-
tion by proton irradiation of 18O-enriched water and delivered to 
the 18F incoming reservoir. The fully automated manufacturing 
process consists of the following steps: trapping of 18F-fluoride 
on a QMA cartridge, elution using Kryptofix®222, potassium 
hydrogen carbonate, water and acetonitrile, azeotropic drying of 
18F-fluoride at 120°C for 9 min, labeling of the precursor in MeCN 
at 100°C for 6 min, dilution of the crude product with water, tC18 
cartridge-based purification by using 20 mL 40% (v/v) Ethanol 
and 11.5  mL 35% (v/v) Ethanol, elution of the product with 
3.5 mL 55% (v/v) Ethanol and final formulation with phosphate 
buffer. Synthesis time was 43  min, radiochemical yield (non-
decay corrected) was 34 ± 9% (n = 18) with radiochemical purity 
≥98%, and specific activity was 1810 ± 616 GBq/μmol (end of 
synthesis).
PeT imaging
PET imaging was performed at the preclinical research divi-
sion of the Department of Nuclear Medicine at the University 
of Munich. For the animal studies, anesthesia was induced with 
isoflurane (as described above), and a cannula was placed in a tail 
vein. Animals were positioned in the Siemens Inveon P120 PET 
scanner (Siemens Medical Solutions, Munich, Germany) and 
were kept warm with a heating pad. To prevent head movements, 
the head position was fixed using a custom-made head holder. A 
bolus of 50 MBq [18F]GE180 in 0.5 ml saline was injected and a 
90-min dynamic emission recording was initiated followed by a 
15-min transmission scan using a rotating [57Co] point source. 
After recovering from anesthesia, the rats were returned to their 
home cages.
image Processing and statistical  
PeT analysis
Emission recordings were corrected for random, coincidences, 
normalized, and reconstructed with iterative reconstruction 
employing the Ordered Subsets Expectation Maximization 
(OSEM-3D) algorithm, which includes scatter and attenuation 
correction (Siemens Medical Solutions Munich, Germany) 
and results in a final 128 ×  128 ×  159 matrix. For attenuation 
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correction, the corresponding transmission measurements at 
the end of the emission scan were used. The voxel dimensions of 
the reconstructed images were 0.78 mm × 0.78 mm × 0.80 mm. 
Further data processing was performed by PMOD (V3.5, PMOD 
Technologies Ltd.). The 60–90  min time frame was selected 
for further analyses as this time frame proved to be suitable in 
a recent in-house investigation in rodents (29). Static datasets 
(60–90  min) were co-registered to a high-resolution rat cryo-
atlas by a manual rigid-body transformation (TXrigid) using 
the PMOD fusion tool (V3.5, PMOD Technologies Ltd.), after 
blinding the rat identity to the reader. In the second step, a reader-
independent fine co-registration to a tracer-specific template was 
performed (30). The template was generated by averaging all PET 
scans. Then, the initial manual PET-to-atlas fusion images were 
normalized by non-linear brain normalization (TXBN) to the 
tracer-specific template using the PMOD brain normalization 
tool (equal modality; smoothing by 0.8 mm; nonlinear warping; 
16 iterations; frequency cutoff 3; regularization 1.0; no threshold-
ing). The concatenation of TXrigid and TXBN was then applied to 
PET datasets in the native space to obtain optimal resampling 
with a minimum of interpolation. [18F]GE180 data were scaled by 
the global cerebral mean. Voxel-wise analyses were conducted by 
custom-made toolboxes, implemented in statistical parametric 
mapping software SPM5 (Wellcome Department of Cognitive 
Neurology, London). Images were used after pre-processing. 
For each timepoint after surgery groups of UL and SHAM-UL, 
rats were compared by an unpaired Student’s t-test. Additionally, 
SHAM-UL rats of all time points were compared against the 
baseline to test for purely surgery-related effects. A statistical 
threshold of p < 0.01 (uncorrected for multiple comparisons) and 
a voxel-threshold of 50 were defined.
Volume-of-interest (VOI) based analyses were performed in 
brain volumes deriving from voxel-wise analyses. Standardized 
uptake value ratios including global mean scaling (SUVRGLM) for 
the ipsilesional VN and nerve were extracted from individual 
animals and used for further group comparisons and correlation 
analyses.
Ex Vivo autoradiography and histology
After completion of the attenuation scans (110 min after injec-
tion of [18F]GE180) four rats per group (UL/SHAM-UL) and 
time point (days 7, 15, 30) after UL/SHAM-UL were sacrificed 
by intracardiac injection of 0.4  mg/kg xylazinhydrochloride 
(Rompun®) in deep isoflurane narcosis. Brains were resected 
and immediately frozen at −80 °C, followed by thermal equi-
libration at −20 °C for 10 min in a Leica CM 1510-1 Cryostat 
(Leica Microsystems, Nussloch Germany). Then the brains were 
cut in 20-μm-thick transverse slices, which were mounted on 
microscope slides (Menzel GmBH, super frost, Germany) and 
placed on Fujifilm BAS cassette2 2025 imaging plates. The plates 
were exposed for 24 h and then scanned at standard resolution, 
25 µm, with the Raytest equipment (CR-Reader Software, v.1.4.1., 
Dürr Medical, Germany). Regions of interest (ROIs) were drawn 
on the ipsi- und contralesional vestibular and facial nucleus 
(FN). The quantitative luminescence value (QL) for each ROI 
was determined using Advanced Image Data Analyzer (AIDA, 
v.4.5), relative to the reference tissue. The reference region was 
determined as the background QL measured in the midline pons 
individually for every brain section. For anatomic coregistration, 
the transverse brain slices, which were used for autoradiography, 
underwent a subsequent Nissl-staining process using established 
protocols (31).
statistics analysis
IBM SPSS Statistics (version 23.0; SPSS, Chicago, IL, USA) was 
used for all statistical tests. Normal distribution was tested by 
the Kolmogorov–Smirnov test. Statistical group comparison 
for behavioral scoring was performed by the non-parametric 
Kruskal–Wallis H test and post  hoc testing with Bonferroni 
correction to analyze significant differences between time 
points after UL. PET SUVRGLM values were compared between 
UL and SHAM-UL groups by an unpaired Student’s t-test. 
Autoradiography QL/pixel values of vestibular and facial nuclei 
were compared between ipsi- and contralateral lesion side by a 
paired Student’s t-test and between UL and SHAM-UL groups by 
an unpaired Student’s t-test. Pearson’s coefficient of correlation 
was calculated between regional TSPO activity (SUVRGLM) and 
changes in postural instability per day. A significance level of 
p < 0.05 was set for rejection of the null hypothesis.
resUlTs
behavioral compensation after Ul
After UL all animals showed severe vestibular imbalance includ-
ing nystagmus, barrel rolling, circular walking, and postural 
instability, whereas no signs of vestibular dysfunction were 
observed after SHAM surgery. These data are comparable with 
results of previous studies using the same UL model (23, 25). In 
the UL group, postural asymmetry significantly improved until 
day 30 (mean postural scores 7.4 ± 2.0 on day 3 versus 4.2 ± 1.3 
on day 15, and versus 2.1 ± 1.2 on day 30). The Kruskal–Wallis 
H test showed that there was a significant difference in postural 
scores between days after UL, χ2(5) = 39.258, p < 0.0005. Post hoc 
tests with Bonferroni correction revealed significant differences 
between days 15 and 2 (z = 3.649, p = 0.004), day 3 (z = 4.440, 
p < 0.0005), and day 7 (z = 3.226, p = 0.019), as well as days 30 
and 2 (z = 4.127, p = 0.001), day 3 (z = 4.789, p < 0.0005), and 
day 7 (z = 3.774, p = 0.002) (Figure 2). Spontaneous nystagmus 
ceased until day 7 (mean nystagmus scores 6.0 ± 2.3 on day 1 
versus 1.9 ± 3.2 on day 3). For nystagmus the Kruskal–Wallis H 
test showed a significant difference between days after UL. Post 
hoc tests indicated significant differences between days 3 and 1 
(z = 3.792, p = 0.002), days 7 and 1 (z = 5.777, p < 0.0005), days 15 
and 1 (z = 4.953, p < 0.0005), days 30 and 1 (z = 4.114, p = 0.001), 
as well as days 7 and 2 (z = 3.843, p = 0.002) and days 15 and 2 
(z = 3.295, p = 0.015) (Figure 2).
[18F]ge180-PeT analysis after Ul versus 
shaM surgery
[18F]GE180-PET scans were performed at baseline and on days 7, 
15, and 30 after UL or SHAM-UL surgery to investigate distribu-
tion and kinetics of TSPO activity in vivo during the later course 
of behavioral compensation. Successfully imaged numbers of rats 
FigUre 2 | Behavioral scores after unilateral labyrinthectomy (UL). Postural imbalance scores decreased significantly until day 30 post-UL (left side), nystagmus until 
day 7 post-UL (right side). Values are depicted as mean ± SD. Significant differences between time points are depicted based on post hoc analysis of the 
Kruskal–Wallis H test: *p < 0.05, **p < 0.005, ***p < 0.0005.
FigUre 3 | Voxel-wise and VOI-based comparison of [18F]GE180-PET images between UL and SHAM-UL groups. (a) In the UL group, translocator protein (TSPO) 
activity was increased in the ipsilesional VN and nerve on day 7 after surgery (UL: N = 10 versus SHAM-UL: N = 6 rats). Both regions indicated still elevated TSPO 
activity at a lower degree on day 15 (UL: N = 10 versus SHAM UL: N = 5 rats). No significant differences in [18F]GE180 accumulation between both groups were 
found on day 30 (UL: N = 4 versus SHAM-UL: N = 5 rats). (b) VOI-based values of single UL rats (N = 10) on day 7 indicate elevated but heterogeneous TSPO 
activation in the vestibular nerve and nucleus when compared to SHAM-UL (N = 6). UL, unilateral labyrinthectomy; R, right; L, left; Ca, caudal; Ro, rostral; VN, 
vestibular nucleus; SUVRGLM, standardized uptake value ratios including global mean scaling; VOI, volume-of-interest.
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are reported in Table 1. TSPO polymorphisms were excluded by 
genetic testing.
SPM-based analysis of group data revealed a strongly elevated 
[18F]GE180 uptake in the ipsilesional VN and nerve at day 7 
post-UL when compared to SHAM-UL (p < 0.01) (Figure 3A). 
[18F]GE180 uptake remained significantly increased in the VN and 
nerve on the lesion side on day 15 post-UL (p < 0.001). On day 30, 
[18F]GE180 accumulation did not indicate a statistical difference 
FigUre 4 | Correlative analysis of SUV [18F]GE180 uptake in the ipsilesional vestibular nucleus (VN) and behavioral scores. (a) [18F]GE180 uptake on day 7 
post-unilateral labyrinthectomy (UL) correlated negatively with the daily changes in postural asymmetry scores of UL rats (N = 10). (b) The negative correlation 
between translocator protein (TSPO) activation in the ipsilesional VN and the degree of compensation was still present for [18F]GE180 uptake on day 15 post-UL 
(N = 9 rats). (c) Exemplary autoradiography at the level of the VN and facial nucleus (FN) (including anatomical verification by histology) from a rat with very fast 
vestibular compensation (VC) until death on day 7 (green, upper image, high [18F]GE180 uptake) and another slice from a rat with very slow VC until death on the 
same day (red, lower image, low [18F]GE180 uptake).
6
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in any brain region when comparing UL and SHAM-UL rats. The 
same [18F]GE180 uptake pattern was found when values for days 
7, 15, and 30 post-UL were compared to baseline. [18F]GE180 
uptake in the SHAM surgery group did not differ from baseline 
at any time point (data not shown).
Volume-of-interest-based analysis in the ipsilesional VN 
indicated a significantly increased [18F]GE180 SUVRGLM after 
UL as compared to SHAM surgery on day 7 [2.05 ± 0.22 versus 
1.68 ±  0.11, t (14) =  4.17, p =  0.0009, Figure 3B] and on day 
15 [1.99 ±  0.12 versus 1.79 ±  0.17, t (13) =  2.48, p =  0.0275], 
whereas [18F]GE180 SUVRGLM was nearly normalized on day 30 
[1.85 ± 0.17 versus 1.78 ± 0.17, t (7) = 0.41, p = 0.6950]. [18F]
GE180 uptake in the ipsilesional vestibular nerve was likewise 
significantly increased on day 7 in the UL group as compared 
to the SHAM surgery group [1.88 ±  0.21 versus 1.52 ±  0.09, t 
(14) =  3.82, p =  0.0019, Figure  3B]. In the same comparison, 
TSPO activity in the nerve was still elevated on day 15 [1.79 ± 0.24 
versus 1.45 ±  0.13, t (13) =  2.66, p =  0.0195], and indicated a 
trend to prolonged elevation on day 30 [1.71  ±  0.12 versus 
1.41 ±  0.17, t (7) =  1.83, p =  0.1095]. Baseline values prior to 
surgery were in the range of SHAM-UL for the VN (1.71 ± 0.08) 
and the vestibular nerve (1.47 ± 0.18).
correlation of TsPO activity and Vc
Correlation analysis of [18F]GE180-PET on day 7 was done with 
parameters of postural asymmetry only as nystagmus remission 
was completed at that time. TSPO activity in the ipsilateral VN on 
day 7 correlated highly with the slope of compensation (assessed 
by postural asymmetry) on the single rat level (r  =  −0.90; 
p <  0.001; Figure 4A). This association was present at a lower 
level when correlating levels of TSPO activity in the ipsilateral 
VN on day 15 with the slope of compensation (r = 0.72; p < 0.05; 
Figure 4B), whereas no significant correlation was found for day 
30. Behavioral scores did not correlate with TSPO activity in the 
ipsilateral vestibular nerve eventually. Exemplary ex vivo auto-
radiography findings on day 7 of two rats with highly different 
compensation slopes confirmed the in vivo findings (Figure 4C).
Ex Vivo [18F]ge180 autoradiography  
and histology
The pattern of [18F]GE180 binding determined by autoradiog-
raphy ex vivo qualitatively resembled the binding differences 
observed in the PET scans. Further quantitative analyses were 
performed in histologically confirmed ROIs (i.e., ipsilesional VN, 
FigUre 5 | Quantitative ROI-based analysis of ex vivo [18F]GE180 autoradiography after UL and SHAM-UL. Significant increases of [18F]GE180 uptake were found 
in the ipsilesional VN on days 7 and 15 after UL, when compared to contralateral, but no significant differences were observed in the VN of SHAM-UL. [18F]GE180 
uptake was consistently elevated in the ipsilateral FN on days 7 and 15 after UL and SHAM-UL, when compared to contralateral (UL/SHAM-UL: N = 4 rats, 
respectively, per time point). UL, unilateral labyrinthectomy; ips, ipilesional; contr, contralesional; VN, vestibular nucleus; FN, facial nucleus; ROI, region of interest. 
*p < 0.05 ipsilateral versus contralateral; #p < 0.05 UL versus SHAM-UL.
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contralesional VN, ipsilesional FN, contralesional FN). The bind-
ing of [18F]GE180 in UL rats was significantly increased sixfold 
in the ipsilesional VN at day 7 and sixfold at day 15 as compared 
to the contralesional VN [t (6)  =  3.16/3.34, both p  <  0.05] 
(Figure 5). In SHAM-UL, there was no significant asymmetry of 
[18F]GE180 binding in the vestibular nuclei. [18F]GE180 binding 
appeared increased by seven- to ninefold in the ipsilesional FN 
on days 7 and 15 in UL and SHAM-UL groups [t (6) = 3.66/2.74, 
both p < 0.05], potentially indicating irritation of the facial nerve 
due to middle ear injection.
DiscUssiOn
To the best of our knowledge, this is the first study to show glial 
activation in vivo during VC in a rat model of a unilateral inner 
ear lesion using a novel TSPO ligand μPET approach. The major 
findings of the study are the following: (1) toxic inner ear damage 
induces a glial activation in the vestibular nerve and nucleus on 
the lesion side within the first 30 days. (2) Glial activation paral-
lels the course of late postural compensation.
[18F]ge180 PeT imaging of glial activation 
during Vc and recovery
The TSPO is a mitochondrial transporter, which has a relatively 
low expression in the healthy CNS. However, various pathologies 
can cause significant upregulation of TSPO expression (16). In 
the past, the TSPO radiotracer ligand [11C]PK11195 was success-
fully applied to depict glial activation in various CNS diseases like 
multiple sclerosis, Huntington’s disease, amyotrophic lateral scle-
rosis, Alzheimer’s disease, traumatic brain injury, and ischemic 
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stroke (32–35). A recent [11C]PK11195-PET study in the rat 
showed spinal glial activation after partial sciatic nerve ligation 
with peaking kinetics at 7–14 days post-lesion (36).
The new second-generation TSPO ligand [18F]GE180 has so 
far not been applied to visualize glial activation in a model of 
peripheral nerve or sensory organ damage (21). We here report 
[18F]GE180 uptake in the vestibular nerve and nucleus with on 
days 7 and 15 post-chemical UL in the rat. Exact localization 
of glial activation was validated by ex vivo autoradiography and 
histology. The dynamics and localization of microglial activation 
depicted by [18F]GE180-PET and autoradiography nicely confirm 
previous data from in  vitro studies (13, 14). A methodological 
advantage of the chemical UL model, which is a sensory end-
organ lesion model, is that cerebral networks remain completely 
intact. Confounding effects of a blood–brain barrier disturbance, 
cerebral perfusion changes, or systemic inflammation on [18F]
GE180 uptake can therefore be ruled out. A further advantage of 
the present study in the UL model is that behavioral changes of 
vestibular imbalance can be easily recorded, quantified, and cor-
related to the [18F]GE180 uptake, which allows further insights 
into the functional relevance of glial activation for behavioral 
compensation after inner ear damage in vivo.
The Functional role of Microglial 
activation in Vc
Past in  vitro studies described microglial activations within the 
VN following inner ear damage by means of mRNA analysis and 
immunostaining (12–14). However, the mechanisms inducing 
central microglial activation after a peripheral vestibulo-cochlear 
damage and the functional relevance of microglial activation for 
VC remain unclear. It has been hypothesized that not the decrease 
in neuronal activity per  se but rather trans-neuronal changes of 
inflammatory cytokines may induce microglial activation in the 
VN (14). Comparative analysis of behavioral and [18F]GE180 
kinetics in our study suggest that microglial activation in the VN 
initially parallels the occurrence of vestibular imbalance measured 
in postural asymmetry scores (Figures 2 and 3). Therefore, it is 
most likely that the vestibular damage trans-neuronally drives glial 
activation along the vestibular nerve and nucleus. Potential mecha-
nisms may be the local modification of neuropeptide expressions, 
cytokines, and growth factors triggered by impending vestibular 
nerve degeneration (19, 37, 38). Interestingly, no other brain region 
besides the ipsilesional VN showed [18F]GE180 uptake.
Our data furthermore suggest that this glial activation in the 
VN may be beneficial for further VC and recovery. Higher [18F]
GE180 binding in the VN, but not vestibular nerve, especially 
on day 7 correlated with faster compensation of postural imbal-
ance (Figure  4). It is well-accepted that structural plasticity 
in the VN and commissural system is a central mechanism 
of VC (3, 9). Glial reaction may counteract a degeneration of 
second-order vestibular neurons and improve recovery of their 
neuronal resting activity and may change balance of excitatory 
and inhibitory neurotransmission in the VN (14). In analogy 
to our data, a potentially beneficial role of glial activation has 
been described in other peripheral nerve disorders (19, 39). 
Microglial activation after peripheral nerve lesion persists as 
long as functional nerve damage is present and ceases only 
upon regeneration (20). Microglial activation by TSPO ligands 
may potentially promote functional recovery in experimental 
peripheral nerve lesions (16, 40).
clinical relevance of Microglial activation 
in aUV
In clinical practice, AUV is the most frequent reason for presenta-
tion of acute vertigo with postural imbalance persisting for days 
to weeks (41). However, the pathophysiology of this clinical dis-
order is not known. Inflammatory changes along the vestibular 
nerve have been hypothesized (41, 42).
What can a rat model of UL contribute to this discussion? 
It definitely shows that even in case of toxic damage to the 
vestibular and cochlear hair cells of the inner ear, there is a 
secondary inflammatory response via microglial activation 
along the vestibular nerve leading to the VN. It could well be 
that secondary degeneration of the Scarpa’s ganglia and the 
vestibular nerve plays a critical role in glial activation during the 
later stages after UL (23). However, the present study shows that 
any damage of the peripheral vestibular system seems to induce 
a reactive neuroinflammation. The data of the current study sug-
gest that conceptually it seems important to think about AUV 
as a disease with various etiologies, which results in a common 
pathophysiological neuroinflammatory response of the first- and 
second-order vestibular neurons.
limitations
The current pilot study aimed to establish in vivo imaging of glial 
activation by means of [18F]GE180-PET in the rat model of chemi-
cal UL. The imaging time points were guided to the later phase of 
VC after day 7. Thereby early mechanismens of VC, happening 
during the first days after UL were neglected. As concerns com-
parative interpretation of PET and behavioral data, the correlation 
of TSPO activity with the slope of postural improvement does not 
equal causation. Therefore, the role of glial activation in VC needs 
further investigation, in order to determine if it is beneficial or 
not. A partial longitudinal study design was chosen to be able 
to compare and validate TSPO activity in PET with the ex vivo 
autoradiography signal in a subset of rats. However, this design 
has the disadvantage that the number of animals drops during the 
experiment. This could cause problems for the statistical assump-
tions, such as homogeneity of variance. Differences in numbers of 
PET scans on day 30 versus days 15 or 7 may contribute to the lack 
of significance in SPM between UL and SHAM-UL at that time 
point. However, ex vivo autoradiography and VOI-based in vivo 
analyses likewise resulted in only minor differences on day 30. In 
summary, differences in glial activity between UL and SHAM-UL 
during the very late phase of VC after UL should be negligible.
cOnclUsiOn
The present rat [18F]GE180-PET study shows in vivo evidence that 
microglial activation appears in the vestibular nerve and nucleus 
following inner ear damage. The model of chemical UL has the 
unique advantage that the vestibular nerve and central networks 
remain structurally intact. This allows investigation of microglial 
reactions without any contamination due to structural cerebral 
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damage. The pattern of glial activation indicates that a reactive 
neuroinflammation of the vestibular nerve and nucleus evolves 
after peripheral deafferentation, which may be beneficial for 
functional recovery.
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